BioLineRx Discloses FDA Authorization for APHEXDA™ (motixafortide), to Activate Hematopoietic Stem Cells for Gathering and Subsequent Autologous Transplantation in Multiple Myeloma Patients.

Takeda has shared positive initial results from its Phase 2b trial, on TAK-279, a selective, orally administered TYK2 inhibitor, which is assessed for its efficacy in treating active psoriatic arthritis.

LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively.

Phase 3 CheckMate-227 Trial's findings confirm enduring, extended survival with Opdivo combined with Yervoy with Metastatic Non-Small Cell Lung Cancer.

Blue Earth Therapeutics released preclinical study results on the potency, lipophilicity, absorption, and efficacy of 225Ac-rhPSMA-10.1 in prostate cancer models, compared to 177Lu-rhPSMA-10.1. Both showed strong binding, excellent absorption, and similar lipophilicity.

Results from the Phase 2 clinical trial examining VGT-309 indicate that the trial drug could enhance surgeons' capacity to locate hard-to-spot and previously missed tumors in real-time, thereby potentially benefitting patient outcomes.

Lassen Therapeutics is developing novel antibody treatments for fibro-inflammatory diseases and cancer, focusing on the IL-11R receptor (LASN01) and interleukin-18 binding proteins.

Positive high-level results from AstraZeneca's MANDARA Phase III study revealed that FASENRA(benralizumab)

MBX Biosciences, Inc. released favorable outcomes from the Phase 1 trial's multiple ascending dose section for MBX 2109.

EyePoint Pharmaceuticals, Inc., a company focused on improving life quality for severe eye condition patients, has revealed promising safety data for its key product candidate EYP-1901.

Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer.

Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.